ORYZON to Provide Corporate Progress Updates at Several Events in January

• 7th Sachs Annual Neuroscience Innovation Forum
• 13rd Annual LifeSci Advisors Corporate Access Event
• Biotech Showcase-2024
• 42nd Annual J.P. Morgan Healthcare Conference
• Invest Securities Biomed Forum 2024
  

MADRID, Spain and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events in January.

Oryzon will participate at the 7th Sachs Annual Neuroscience Innovation Forum, which will be held on January 7 at the Marine’s Memorial Club in San Francisco (USA). The company will take part in a panel entitled “New Approaches to Neuro Psychiatric Disorders Panel” at 1:00 pm PST and will provide a corporate update on its CNS program at 3:30 pm PST. Click on link for more info about 7^th Sachs Annual Neuroscience Innovation Forum

Oryzon will participate at the 13^th Annual LifeSci Advisors Corporate Access Event, which will be held at the Beacon Grand Hotel in San Francisco (USA) on January 8-10, where the company will provide a corporate update to investors and will maintain a set of meetings with pharma companies. Click on link for more info about the 13^th Annual LifeSci Advisors Corporate Access Event

Oryzon will participate at the Biotech Showcase 2024 Event, which will take place at the Hilton Union Square hotel in San Francisco (USA) on January 8-10. Oryzon will provide a corporate update on January 9 at 2:30 pm PST and maintain a set of meetings with pharma companies. Click on link for more info about the Biotech Showcase 2024

Oryzon has been invited to participate at the 42nd Annual J.P. Morgan Healthcare Conference, which will be held on January 8-11 at the Westin St. Francis Hotel in San Francisco (USA). Click on link for more info about the Annual JP Morgan Healthcare conference

Oryzon will also attend the Invest Securities Biomed Forum 2024, which will be held in Paris (France) on January 30.

About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS and iadademstat in oncology, in several Phase II clinical trials. The company has other pipeline assets directed against other epigenetic targets. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com